Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir
暂无分享,去创建一个
[1] J. Dawson,et al. Spectroscopic investigations of ferric cytochrome P-450-CAM ligand complexes. Identification of the ligand trans to cysteinate in the native enzyme. , 1982, The Journal of biological chemistry.
[2] S. Vasavanonda,et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[3] J. Zou,et al. Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.
[4] Ortiz de Montellano,et al. Cytochrome P-450: Structure, Mechanism, and Biochemistry , 1986 .
[5] F. Berthou,et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[6] A. Munro,et al. Determination of the redox properties of human NADPH-cytochrome P450 reductase. , 2001, Biochemistry.
[7] W. Pryor. Cytochrome P450: Structure, mechanism, and biochemistry , 1996 .
[8] T. Shimada,et al. Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[9] C. Jefcoate,et al. Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. , 1978, Methods in enzymology.
[10] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[11] S. Sligar,et al. Electron transfer in the complex of membrane-bound human cytochrome P450 3A4 with the flavin domain of P450BM-3: the effect of oligomerization of the heme protein and intermittent modulation of the spin equilibrium. , 2010, Biochimica et biophysica acta.
[12] Y. Berger,et al. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[13] T. Sjögren,et al. Structural basis for ligand promiscuity in cytochrome P450 3A4 , 2006, Proceedings of the National Academy of Sciences.
[14] H. Yamazaki,et al. Lack of Electron Transfer from Cytochrome b5 in Stimulation of Catalytic Activities of Cytochrome P450 3A4 , 1996, The Journal of Biological Chemistry.
[15] S. Sligar,et al. Spin state control of the hepatic cytochrome P450 redox potential. , 1979, Biochemical and biophysical research communications.
[16] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[17] R. Silverman. Mechanism-based enzyme inactivation : chemistry and enzymology , 1988 .
[18] M Hendlich,et al. LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins. , 1997, Journal of molecular graphics & modelling.
[19] F Peter Guengerich,et al. Kinetics and Thermodynamics of Ligand Binding by Cytochrome P450 3A4* , 2006, Journal of Biological Chemistry.
[20] D. Greenblatt,et al. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors , 2000, Biological Psychiatry.
[21] L. Pershing,et al. Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics; a new class of agents. , 1982, Xenobiotica; the fate of foreign compounds in biological systems.
[22] M. Desai,et al. Pharmacokinetic enhancers for HIV drugs. , 2009, Current opinion in investigational drugs.
[23] A. Das,et al. Redox potential control by drug binding to cytochrome P450 3A4. , 2007, Journal of the American Chemical Society.
[24] F. Guengerich. Oxidation-reduction properties of rat liver cytochromes P-450 and NADPH-cytochrome p-450 reductase related to catalysis in reconstituted systems. , 1983, Biochemistry.
[25] Eric F. Johnson,et al. The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.
[26] T. Omura,et al. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. , 1964, The Journal of biological chemistry.
[27] M. J. Coon,et al. Purified liver microsomal cytochrome P-450. Electron-accepting properties and oxidation-reduction potential. , 1975, The Journal of biological chemistry.
[28] D. Greenblatt,et al. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole , 2000, European Journal of Clinical Pharmacology.
[29] A. D. Rodrigues,et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.
[30] H. Yamazaki,et al. Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH--cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates. , 1995, Biochemistry.
[31] Jose Cosme,et al. Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.
[32] Karthik Venkatakrishnan,et al. Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions , 2007, Drug Metabolism and Disposition.
[33] C. Ernest,et al. Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors , 2005, Journal of Pharmacology and Experimental Therapeutics.
[34] J. Bridges,et al. Structure--activity relationship for 'safrole-type' cytochrome P-450 induction [proceedings]. , 1979, Biochemical Society Transactions.
[35] P. Vouros,et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[36] D. Back,et al. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. , 2003, British journal of clinical pharmacology.
[37] F. Guengerich,et al. Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems. , 1997, Biochemistry.
[38] J. Dawson,et al. The diverse spectroscopic properties of ferrous cytochrome P-450-CAM ligand complexes. , 1983, The Journal of biological chemistry.
[39] J. Lin,et al. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. , 1996, Drug metabolism and disposition: the biological fate of chemicals.